The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

“Everybody’s on pins and needles because we don’t know exactly what’s going to come out of this,” Smart said. Football rosters are expected to be capped at 105 players, but Smart said ...

A trial for a drug needle waste bin has been approved for a Belfast city centre car park behind Central Library. Elected representatives at a Belfast City Council committee meeting this week ...

The weight management firm has been struggling to stay relevant as highly effective weight-loss drugs, such as Novo Nordisk’s Wegovy, soared to popularity by offering a quicker fix to obesity ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

A certified sleep science coach and mattress expert, JD has been reviewing online mattresses professionally for the past five years. During that time, he's tested well over 150 beds and dedicated ...

You can use Wegovy (semaglutide) as long as you need for weight loss and weight management. You can continue taking Wegovy if you and your doctor determine that Wegovy is safe for you and you can ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis. Obesity is ...

Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat type 2 diabetes and Wegovy for managing overweight or obesity. GLP-1 is a hormone produced by the intestines.

But, while Novo’s Ozempic and Wegovy for diabetes and obesity are already quite popular in the country, the drugs’ active ingredient, semaglutide, is slated to lose patent protection in Brazil ...

Danish pharmaceutical company Novo Nordisk plans to introduce its weight-loss drug Wegovy in India earlier than planned to compete with Eli Lilly's Mounjaro. Previously set for 2026, the launch might ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. Top of the morning to you, and a fine one it is. Blue skies ...